MedTrace Logo

Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive

NCT01737450 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2019-06-24

No results posted yet for this study

Summary

The aim of this study is to determine the activity, to assess the safety and tolerance of BKM120 in adult patients with recurrent or metastatic head and neck cancer progressive under platin and cetuximab-based chemotherapy.

Conditions

  • Head and Neck Neoplasms
  • Neoplasm Metastasis
  • Recurrent Disease
  • Progressive Disease

Interventions

DRUG

BKM120

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Fondation ARC

    collaborator OTHER

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Jérome FAYETTE, MD · Centre Léon Bérard, Lyon- FRANCE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2018-09-30
Completion
2019-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01737450 on ClinicalTrials.gov